The Centers for Medicare and Medicaid Services will adjust monthly Part B premiums downward in 2023 to reflect the fact that Medicare reimbursement for Biogen, Inc.’s Alzheimer’s drug Aduhelm has been strictly limited to its use in randomized clinical trials, and that Biogen has cut the drug’s price in half, the agency announced on 27 May.
The announcement responds to a directive from Health and Human Services Department Secretary Xavier Becerra that CMS rethink the unprecedented...







